PATENT CLAIM ANALYSIS

Application Number: 16207611
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "085200"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 78):
A method for delivering an interleukin-22 to a subject, the method comprising orally delivering to the subject a pharmaceutical composition comprising (i) a carrier consisting of the amino acid sequence set forth in SEQ ID NO: 1 or a fragment thereof, wherein the fragment of the amino acid sequence set forth in SEQ ID NO: 1 consists of the amino acid sequence set forth in any one of SEQ ID NOS: 3, 42, 52, 70, or 80, and wherein the carrier is conjugated to (ii) the interleukin-22 consisting of at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 85 or a fragment thereof.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16207637', '15309177', '15616140', '13946313', '13822435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7118436765057372
- 35 USC 102 Novelty (BERT): 0.5924795092494429
- Combined Prediction Score: 0.6999072597801078
- Mean Citation Score: 387.659464
- Max Citation Score: 528.54407
- Similarity Product: 434.0735706166751

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test